Pharmacology, Toxicology and Pharmaceutical Science
Rheumatoid Arthritis
100%
Tumor Necrosis Factor
45%
Disease Modifying Antirheumatic Drug
32%
Tumor Necrosis Factor Inhibitor
31%
Tumor Necrosis
28%
Biological Product
18%
Infection
15%
Disease
15%
Disease Activity
14%
Psoriatic Arthritis
14%
Etanercept
13%
Observational Study
13%
Rituximab
11%
Infliximab
11%
Malignant Neoplasm
8%
Adalimumab
8%
Remission
6%
Tocilizumab
6%
Methotrexate
6%
Interstitial Lung Disease
5%
Necrosis
5%
Ankylosing Spondylitis
5%
Juvenile Rheumatoid Arthritis
5%
Inflammatory Arthritis
5%
Standardized Incidence Ratio
5%
Medicine and Dentistry
Rheumatoid Arthritis
87%
Tumor Necrosis Factor
40%
TNF Inhibitor
24%
Disease Modifying Antirheumatic Drug
24%
Biological Product
23%
Tumor Necrosis
20%
DAS28
11%
Rituximab
11%
Observational Study
10%
Disease Activity
10%
Etanercept
10%
Disease-Modifying Antirheumatic Drug
9%
Malignant Neoplasm
9%
Diseases
8%
Health Assessment Questionnaire
8%
Psoriatic Arthritis
8%
Infliximab
8%
Population
7%
Infection
6%
Standardized Incidence Ratio
6%
Necrosis
6%
Methotrexate
6%
Interstitial Lung Disease
5%
Juvenile Idiopathic Arthritis
5%
Low Back Pain
5%
Tocilizumab
5%
Hazard Ratio
5%
Biological Therapy
5%
Nursing and Health Professions
Rheumatoid Arthritis
30%
Tumor Necrosis Factor
14%
Tumor Necrosis Factor Inhibitor
11%
Rituximab
11%
Biological Product
9%
Etanercept
8%
Disease Modifying Antirheumatic Drug
7%
Disease
6%
Infection
6%
Biosimilar Agent
5%
Juvenile Rheumatoid Arthritis
5%
Low Back Pain
5%
Health Assessment Questionnaire
5%
